Xenia Gonda, Peter Dome, Gianluca Serafini & Maurizio Pompili. (2023) How to save a life: From neurobiological underpinnings to psychopharmacotherapies in the prevention of suicide. Pharmacology & Therapeutics 244, pages 108390.
Crossref
Mujeeb U. Shad. (2023) Seventy Years of Antipsychotic Development: A Critical Review. Biomedicines 11:1, pages 130.
Crossref
Glenn A. Melvin, Maria A. Oquendo, Barbara Stanley & Kelly Posner. 2020. Tasman’s Psychiatry. Tasman’s Psychiatry
1
32
.
Leonardo Tondo & Ross J. Baldessarini. 2021. Ketamine for Treatment-Resistant Depression. Ketamine for Treatment-Resistant Depression
85
115
.
J.W.Y. Yuen, C. Wu, C.K. Wang, D.D. Kim, R.M. Procyshyn, W.G. Honer & A.M. Barr. (2020) A comparison of the effects of clozapine and its metabolite norclozapine on metabolic dysregulation in rodent models. Neuropharmacology 175, pages 107717.
Crossref
Sean Bordelon & Stephen H. Dinwiddie. (2017) Possible Antidotes for Suicide Risk: What Should We Tell Our Patients?. Psychiatric Annals 47:9, pages 466-470.
Crossref
Leonardo Tondo & Ross J. Baldessarini. (2016) Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment. Current Psychiatry Reports 18:9.
Crossref
Andreas Hartmann, Steven Whitebread, Jacques Hamon, Alexander Fekete, Christian Trendelenburg, Patrick Y. Müller & László Urbán. 2015. Antitargets and Drug Safety. Antitargets and Drug Safety
457
478
.
Glenn A. Melvin, Kelly Posner, Barbara H. Stanley & Maria A. Oquendo. 2015. Psychiatry. Psychiatry
2492
2505
.
X. Fan, C. P. C. Borba, P. Copeland, D. Hayden, O. Freudenreich, D. C. Goff & D. C. Henderson. (2012) Metabolic effects of adjunctive aripiprazole in clozapine‐treated patients with schizophrenia. Acta Psychiatrica Scandinavica 127:3, pages 217-226.
Crossref
Renan P. Souza, Vincenzo De Luca, Mirko Manchia & James L. Kennedy. (2011) Are serotonin 3A and 3B receptor genes associated with suicidal behavior in schizophrenia subjects?. Neuroscience Letters 489:3, pages 137-141.
Crossref
Rebecca Schennach-Wolff, Florian Seemüller, Richard Musil, Ilja Spellmann, Hans-Jürgen Möller & Michael Riedel. 2011. Handbook of Schizophrenia Spectrum Disorders, Volume III. Handbook of Schizophrenia Spectrum Disorders, Volume III
365
382
.
M.A. Crocq, D. Naber, M.H. Lader, F. Thibaut, M. Drici, B. Everitt, G.C. Hall, C. Le Jeunne, A. Mittoux, J. Peuskens, S. Priori, M. Sturkenboom, S.H.L. Thomas, P. Tanghøj, M. Toumi, R. Mann & N.D. Moore. (2010) Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. European Neuropsychopharmacology 20:12, pages 829-838.
Crossref
Paddy Power. 2010. Promoting Recovery in Early Psychosis. Promoting Recovery in Early Psychosis
180
190
.
Paddy Power & Jo Robinson. 2009. The Recognition and Management of Early Psychosis. The Recognition and Management of Early Psychosis
257
282
.
UE LangM. Willbring, R. von Golitschek, A. Schmeisser, K. Matschke & S Malte Tugtekin. (2008) Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. Journal of Psychopharmacology 22:5, pages 576-580.
Crossref
Trino Baptista, Yamily ElFakih, Euderruh Uzcátegui, Ignacio Sandia, Eduardo Tálamo, Enma Araujo de Baptista & Serge Beaulieu. (2008) Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain. CNS Drugs 22:6, pages 477-495.
Crossref
I. Neuner, F. Schneider & W. Niebling. 2008. Psychische Erkrankungen in der Hausarztpraxis. Psychische Erkrankungen in der Hausarztpraxis
547
553
.
Pierluigi Onali & Maria C Olianas. (2006) N-Desmethylclozapine, a Major Clozapine Metabolite, Acts as a Selective and Efficacious δ-Opioid Agonist at Recombinant and Native Receptors. Neuropsychopharmacology 32:4, pages 773-785.
Crossref
Henrik Lublin, Jonas Eberhard & Sten Levander. (2005) Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. International Clinical Psychopharmacology 20:4, pages 183-198.
Crossref